Top Cancer Drug & Biotech Companies in 2026: Oncology Leaders, Gene Therapy & Next-Generation Cancer Treatment

OneDayMD Oncology Intelligence • 2026 Update

From Keytruda and CAR-T to antibody-drug conjugates, radioligand therapy and Gendicine gene therapy.

Reviewed/updated: September 2026

The global cancer-treatment industry is entering a new era. Oncology is no longer defined simply by chemotherapy and conventional small-molecule drugs. The modern cancer-treatment ecosystem includes immune checkpoint inhibitors, targeted therapies, antibody-drug conjugates (ADCs), bispecific antibodies, CAR-T cells, radioligand therapies, protein degraders, cancer vaccines, oncolytic viruses and gene therapies.

This updated 2026 review therefore looks beyond a simple sales ranking. It evaluates the world's leading cancer-drug and biotechnology companies according to oncology commercial scale, therapeutic innovation, pipeline strength, platform technology, strategic importance and potential influence on the future of cancer treatment.

Key takeaway: Merck remains one of the dominant forces in oncology because of Keytruda, while Roche, Bristol Myers Squibb, Johnson & Johnson and AstraZeneca remain major global players. At the same time, Novartis, Eli Lilly, AbbVie, Pfizer and other companies are expanding their oncology platforms. Beyond conventional pharmaceutical rankings, gene therapy provides another important chapter in oncology history: Gendicine (rAd-p53) became the first commercially approved human cancer gene therapy when China approved it in 2003 for head and neck cancer.

In This Article

1. Executive Summary
2. How the Companies Were Ranked
3. Top Cancer Drug & Biotech Companies in 2026
4. 1. Merck & Co.
5. 2. Roche
6. 3. Bristol Myers Squibb
7. 4. Johnson & Johnson
8. 5. AstraZeneca
9. 6. Novartis
10. 7. Eli Lilly
11. 8. AbbVie
12. 9. Pfizer
13. 10. Astellas Pharma
14. Gendicine: The Cancer Gene-Therapy Pioneer
15. 2026 Oncology Innovation Matrix
16. The Future of Cancer Drugs
17. Limitations
18. Frequently Asked Questions
19. Selected References

Executive Summary

Cancer remains one of the world's largest therapeutic areas, but the competitive structure of oncology is changing rapidly. The industry's centre of gravity is shifting from traditional cytotoxic chemotherapy toward increasingly precise biological interventions.

In 2025, Merck's Keytruda/Keytruda Qlex generated approximately $31.7 billion in sales, illustrating the extraordinary commercial importance of immune checkpoint inhibition. Bristol Myers Squibb reported approximately $10.0 billion in Opdivo revenue in 2025, while Johnson & Johnson reported approximately $25.4 billion in worldwide oncology sales. These figures demonstrate why established oncology franchises remain commercially powerful even as newer platforms emerge.

At the same time, 2026 regulatory activity illustrates the diversification of oncology. Recent approvals have included targeted RAS inhibition, HER2-directed combinations, protein degradation, radioligand therapy, genetically modified oncolytic viral therapy, engineered cell therapies and increasingly biomarker-defined indications.

2026 evidence update: The U.S. FDA's oncology approval database documents multiple 2026 approvals across targeted therapy, immunotherapy, radioligand therapy, engineered cell therapy, antibody-drug conjugates and genetically modified viral therapy. This reinforces the conclusion that oncology innovation is increasingly platform-driven rather than dependent on a single drug class.

How the Companies Were Ranked

There is no single universally accepted definition of the "largest" or "best" cancer-drug company. A company can dominate oncology revenue while having a weaker pipeline, whereas a smaller biotechnology company can possess a highly influential technology platform without generating comparable sales.

This ranking therefore considers six broad dimensions:

• Oncology revenue and commercial scale
• Importance of marketed cancer therapies
• Pipeline depth and late-stage development
• Therapeutic-platform diversity
• Recent regulatory and clinical momentum
• Strategic influence on the future of oncology

The ranking is therefore an editorial assessment rather than an official industry ranking. Revenue figures are not perfectly comparable because companies report oncology using different accounting categories and geographic definitions.

Top Cancer Drug & Biotech Companies in 2026

Rank	Company	Major Oncology Strengths	2026 Strategic Position
1	Merck & Co.	Keytruda, Welireg, Lynparza, Reblozyl	Global immuno-oncology leader
2	Roche	Tecentriq, Alecensa, Kadcyla, Polivy, Vabysmo-related diagnostics ecosystem	Oncology + diagnostics + precision medicine
3	Bristol Myers Squibb	Opdivo, Yervoy, Breyanzi, Abecma, Opdualag	Immunotherapy + cell therapy
4	Johnson & Johnson	Darzalex, Carvykti, Tecvayli, Talvey, Rybrevant	Multiple myeloma + engineered cell therapy
5	AstraZeneca	Tagrisso, Imfinzi, Enhertu partnership, Lynparza, Calquence	Targeted therapy + ADC + immunotherapy
6	Novartis	Kisqali, Pluvicto, Lutathera, Tafinlar/Mekinist	Radioligand therapy + precision oncology
7	Eli Lilly	Verzenio, Jaypirca, Retevmo	Targeted oncology expansion
8	AbbVie	Imbruvica, Venclexta partnership, Elahere	Hematologic cancer + ADC growth
9	Pfizer	Ibrance, Xtandi partnership, Padcev partnership	Breast cancer + targeted and ADC portfolio
10	Astellas Pharma	Xtandi, Padcev partnership, Xospata, Pluvicto-related competitive landscape	Genitourinary oncology + targeted therapies

1. Merck & Co.

#1 — Oncology Scale & Immunotherapy

Merck & Co. — Keytruda and the Immuno-Oncology Era

Merck remains one of the most influential oncology companies in the world, primarily because of Keytruda (pembrolizumab), the PD-1 inhibitor that helped transform immune checkpoint blockade into a central pillar of modern cancer treatment.

Keytruda 2025 sales Approximately $31.7 billion

2025 total company sales Approximately $65.0 billion

Merck's oncology strategy extends beyond Keytruda into targeted therapy and combination approaches. Welireg, Lynparza and Reblozyl contribute to a broader oncology portfolio.

The strategic challenge for Merck is also unusually important: Keytruda's enormous commercial success means the company must successfully transition its oncology franchise toward next-generation combinations and new mechanisms as exclusivity pressures increase.

2. Roche

#2 — Oncology + Diagnostics

Roche — Precision Oncology at Global Scale

Roche occupies a unique position because it combines a major pharmaceutical oncology business with one of the world's largest diagnostic businesses. This combination supports a precision-medicine model in which molecular testing can help identify patients most likely to benefit from targeted therapies.

Its oncology portfolio spans immunotherapy, targeted treatment, antibody-drug conjugates and hematologic malignancies. Key assets and platforms include Tecentriq, Alecensa, Kadcyla and Polivy.

Roche's long-term competitive advantage is therefore not simply its individual drugs. It is the integration of diagnostics, biomarkers, drug development and personalized treatment selection.

3. Bristol Myers Squibb

#3 — Immunotherapy + Cell Therapy

Bristol Myers Squibb — From Checkpoint Inhibitors to CAR-T

Bristol Myers Squibb remains one of the defining companies of modern immuno-oncology. Its Opdivo (nivolumab) and Yervoy (ipilimumab) franchises helped establish immune checkpoint blockade as a major therapeutic approach.

Opdivo 2025 revenue Approximately $10.0 billion

2025 R&D investment Approximately $10.0 billion

BMS has also expanded substantially into cellular therapy through products such as Breyanzi and Abecma. This creates a strategic bridge between conventional pharmaceutical oncology and genetically engineered immune-cell therapies.

The company's oncology future increasingly depends on combinations, new immune targets, cell therapy and next-generation targeted approaches.

4. Johnson & Johnson

#4 — Hematologic Oncology + Cell Therapy

Johnson & Johnson — Multiple Myeloma and Engineered Cell Therapy

Johnson & Johnson has developed one of the strongest modern oncology franchises in multiple myeloma. Darzalex (daratumumab), Carvykti (ciltacabtagene autoleucel), Tecvayli and Talvey form a portfolio spanning monoclonal antibodies, CAR-T and bispecific immune therapies.

2025 oncology sales Approximately $25.4 billion

Carvykti 2025 sales Approximately $1.89 billion

The rapid growth of Carvykti is particularly important. It demonstrates how a company can evolve from conventional pharmaceutical products toward highly engineered cellular therapies.

J&J is also expanding in solid tumors through the Rybrevant/Lazcluze combination and other targeted strategies.

5. AstraZeneca

#5 — Targeted Therapy + ADC + Immunotherapy

AstraZeneca — One of the Most Oncology-Focused Global Pharma Companies

AstraZeneca has become one of the most oncology-focused multinational pharmaceutical companies, with major franchises in lung cancer, breast cancer, ovarian cancer and hematologic malignancies.

Tagrisso remains a major targeted therapy for EGFR-mutated lung cancer, while Imfinzi provides an important immunotherapy franchise. Lynparza extends the company's precision-oncology footprint through PARP inhibition.

AstraZeneca has also strengthened its antibody-drug conjugate strategy through its partnership with Daiichi Sankyo, particularly around Enhertu and other next-generation ADC programs.

The company's 2026 momentum illustrates a broader oncology trend: combining molecularly targeted treatment with immune therapy and increasingly sophisticated biomarker selection.

6. Novartis

#6 — Radioligand Therapy + Precision Oncology

Novartis — The Radiopharmaceutical Revolution

Novartis has developed a distinctive position in oncology through radioligand therapy. Rather than relying exclusively on systemic chemotherapy or conventional targeted drugs, radioligand therapy combines a molecular targeting component with a radioactive payload.

Pluvicto, a PSMA-directed radioligand therapy, has become a major example of this approach in prostate cancer. Lutathera demonstrated the potential of targeting somatostatin receptors in neuroendocrine tumors.

Kisqali has also become an increasingly important breast-cancer franchise. Novartis reported 2025 Kisqali sales of approximately $4.78 billion, up strongly year over year.

Novartis therefore represents one of the clearest examples of how oncology is moving toward molecular targeting plus highly localized therapeutic payloads.

7. Eli Lilly

#7 — Targeted Oncology Expansion

Eli Lilly — Building a Larger Precision-Oncology Franchise

Eli Lilly is better known to the general public for diabetes and metabolic medicines, but its oncology business has become strategically important.

Verzenio (abemaciclib) is a major CDK4/6 inhibitor used in hormone receptor-positive breast cancer. Jaypirca (pirtobrutinib) expands Lilly's position in B-cell malignancies, while Retevmo (selpercatinib) targets cancers driven by RET alterations.

The 2026 traditional approval of selpercatinib for RET fusion-positive solid tumors illustrates an important trend: cancer treatment is increasingly defined by molecular alterations rather than anatomical tumor location alone.

8. AbbVie

#8 — Hematologic Cancer + ADC

AbbVie — Hematologic Malignancies and Next-Generation Targeting

AbbVie's oncology portfolio includes major contributions to hematologic malignancies, particularly through Imbruvica and its partnerships.

The company has also expanded its oncology strategy into antibody-drug conjugates and other targeted biological approaches. Elahere, an ADC targeting folate receptor alpha, represents the growing importance of delivering cytotoxic payloads selectively to cancer cells.

AbbVie's position illustrates how modern oncology increasingly combines conventional pharmacology with precision delivery technologies.

9. Pfizer

#9 — Breast Cancer + Targeted Therapies + ADC

Pfizer — A Broad Oncology Portfolio Undergoing Transformation

Pfizer has long maintained a substantial oncology presence, with Ibrance remaining one of the most recognizable CDK4/6 inhibitors in breast cancer.

The company's oncology strategy has increasingly emphasized targeted therapies, antibody-drug conjugates and external innovation through acquisitions and partnerships.

The changing competitive environment means Pfizer must balance mature oncology products with newer targeted and immune-based therapies.

10. Astellas Pharma

#10 — Genitourinary Oncology

Astellas — A Major Force in Prostate and Genitourinary Cancer

Astellas has built a particularly strong position in genitourinary oncology. Xtandi (enzalutamide), developed with partners, has been a major androgen-receptor pathway therapy in prostate cancer.

Astellas also participates in the antibody-drug conjugate space through Padcev, strengthening its exposure to bladder and urothelial cancers.

Its position demonstrates the continued importance of therapeutic specialization: a company does not need to dominate every cancer type to become a major oncology innovator.

Gendicine: The Cancer Gene-Therapy Pioneer

Why Gendicine belongs in this article: Gendicine should not be ranked against Merck or Roche by pharmaceutical revenue. Its importance is technological and historical. It represents one of the earliest successful examples of a commercially approved cancer gene therapy and provides a bridge between conventional oncology and today's rapidly expanding gene- and cell-therapy ecosystem.

What Is Gendicine?

Gendicine, also known as recombinant human adenovirus-p53 (rAd-p53), is a genetically engineered adenoviral gene therapy developed by Shenzhen SiBiono GeneTech.

China approved Gendicine in 2003 for the treatment of head and neck squamous cell carcinoma. It entered the commercial market in 2004. Peer-reviewed literature describes it as the first commercially approved human cancer gene therapy.

The treatment uses a replication-defective adenoviral vector to deliver a functional wild-type TP53 gene. The objective is to restore p53 tumor-suppressor activity in tumor cells.

Characteristic	Gendicine
Generic description	Recombinant human p53 adenovirus
Common designation	rAd-p53 / Ad-p53
Therapeutic category	Gene therapy
Vector	Replication-defective adenovirus
Therapeutic gene	Wild-type TP53
Developer	Shenzhen SiBiono GeneTech
First approval	China, 2003
Original approved cancer	Head and neck squamous cell carcinoma

Why p53 Matters in Cancer

TP53 encodes the p53 tumor-suppressor protein, one of the central regulators of cellular responses to DNA damage and other forms of cellular stress. p53 participates in cell-cycle control, apoptosis, DNA repair, cellular senescence and other biological processes.

TP53 alterations are extremely common across human cancers. This makes restoration or reactivation of p53 function an attractive therapeutic concept, although translating that biological rationale into durable clinical benefit remains challenging.

How Gendicine Works

1. The recombinant adenoviral vector is delivered to tumor tissue.
2. The vector introduces the functional TP53 gene into susceptible cells.
3. The transferred gene produces functional p53 protein.
4. Restored p53 activity can promote cell-cycle arrest and apoptosis.
5. The therapy may also interact with the tumor microenvironment and immune response.

Gendicine is historically important because it demonstrated that cancer treatment could move beyond administering a chemical or antibody toward deliberately introducing therapeutic genetic information into tumor tissue.

Gendicine and Combination Therapy

Published clinical literature has evaluated Gendicine in combination with radiotherapy, chemotherapy and other treatments. Reviews have reported potentially greater anti-tumor activity when rAd-p53 is combined with conventional therapy than when either approach is used alone in selected settings.

Importantly, however, this evidence should not be interpreted as proof that Gendicine is an effective treatment for every cancer. Much of the clinical experience has been generated in China, studies vary substantially in design and many reports are not equivalent to large, contemporary randomized international trials.

Gendicine Is Not the Same as an Oncolytic Virus

Gendicine is sometimes grouped broadly with virus-based cancer therapies, but there is an important mechanistic distinction.

Gendicine uses a replication-defective adenoviral vector primarily as a gene-delivery system. By contrast, oncolytic viruses are generally engineered to replicate preferentially within tumor cells and destroy them through viral replication and associated immune mechanisms.

This distinction is increasingly important as the oncology field develops multiple viral platforms.

Gendicine's Place in the 2026 Oncology Landscape

Gendicine should therefore be viewed as a gene-therapy milestone rather than as a direct commercial competitor to Keytruda, Opdivo or other global blockbuster medicines.

Its significance becomes clearer when placed alongside today's technologies:

• CAR-T cells genetically engineered outside the body
• Gene-replacement therapies
• Gene-editing approaches
• Oncolytic viral therapies
• mRNA-based cancer vaccines
• Personalized neoantigen vaccines
• Bispecific immune-cell engagers
• Targeted protein degradation
• Antibody-drug conjugates

The FDA's 2026 oncology approvals illustrate how rapidly this technology spectrum is expanding, including approval of a genetically modified oncolytic viral therapy in combination with nivolumab for advanced melanoma.

Important regulatory distinction: Gendicine was approved in China for a specific indication. Approval in one jurisdiction does not mean that a therapy is approved, routinely available or recommended in another country. Patients should not assume that an overseas regulatory approval applies to their local healthcare system.

2026 Oncology Innovation Matrix

The most important development in oncology is arguably not the competition between individual companies but the convergence of multiple therapeutic platforms.

Platform	Examples	Primary Strategy	2026 Significance
Checkpoint immunotherapy	Keytruda, Opdivo, Yervoy	Remove immune inhibition	Established backbone of modern oncology
Targeted therapy	Tagrisso, Retevmo, Kisqali	Block molecular drivers	Increasingly biomarker-defined
Antibody-drug conjugates	Enhertu, Kadcyla, Padcev, Elahere	Targeted delivery of cytotoxic payloads	One of the fastest-growing oncology platforms
Bispecific antibodies	Tecvayli, Talvey and others	Bring immune cells and cancer cells together	Rapidly expanding in hematologic cancers
CAR-T	Carvykti, Breyanzi, Abecma	Genetically engineer immune cells	Major advance in blood cancers
Radioligand therapy	Pluvicto, Lutathera	Deliver radioactive payloads to molecular targets	Expanding precision-radiation strategy
Gene therapy	Gendicine	Deliver therapeutic genetic material	Historically important foundation for cancer gene therapy
Oncolytic viruses	Genetically modified viral therapies	Selective viral attack + immune activation	Renewed clinical momentum
Protein degraders	Next-generation targeted degraders	Remove disease-driving proteins	Emerging precision platform
Personalized cancer vaccines	mRNA/neoantigen platforms	Train immunity against tumor-specific antigens	High potential but mixed clinical evidence

The Future of Cancer Drugs: From Molecules to Biological Engineering

The next decade of oncology is unlikely to be dominated by a single therapeutic class.

Instead, the industry is moving toward multi-platform precision oncology.

A patient may increasingly be characterized not simply by cancer type and stage but by a multidimensional molecular profile including mutations, gene fusions, protein expression, immune biomarkers, tumor mutational burden, microsatellite instability, circulating tumor DNA and other biological characteristics.

Treatment can then be constructed around the biology of that particular tumor.

1. Immunotherapy Will Become More Combinatorial

PD-1/PD-L1 blockade has become a foundation of cancer treatment, but the next generation increasingly involves combinations with targeted therapy, ADCs, chemotherapy, radiotherapy, bispecific antibodies and other immune-modulating approaches.

2. ADCs May Become a Major Oncology Platform

Antibody-drug conjugates combine molecular targeting with a therapeutic payload. This creates the possibility of delivering potent cytotoxic agents more selectively than conventional systemic chemotherapy.

3. Cell Therapy Will Expand Beyond Current CAR-T Indications

CAR-T has produced some of the most dramatic responses seen in certain blood cancers. Research is increasingly focused on improving persistence, reducing toxicity, overcoming antigen escape and extending cell therapy to solid tumors.

4. Radioligand Therapy Could Transform Precision Radiation

Radioligand therapy provides a molecular targeting mechanism for delivering radiation directly to cells expressing a particular receptor or antigen. Its expansion is one of the most important developments in precision oncology.

5. Gene Therapy May Re-emerge Through Better Delivery

Gendicine demonstrated the basic concept of therapeutic gene delivery in cancer. Modern research is exploring improved viral vectors, nanoparticles, RNA technologies and gene-editing systems that could potentially overcome some of the limitations of earlier approaches.

6. AI Will Accelerate Drug Discovery

Artificial intelligence is increasingly being incorporated into target identification, drug discovery, biomarker discovery, patient selection and clinical-trial design. Partnerships between major pharmaceutical companies and AI-biotechnology companies are becoming a significant part of oncology R&D.

What Patients Should Understand About the Oncology Revolution

Rapid innovation does not mean that every new cancer technology is clinically proven for every patient.

The distinction between biological plausibility, laboratory evidence, early clinical evidence, randomized-trial evidence and regulatory approval remains essential.

A therapy can be scientifically fascinating yet still lack sufficient evidence to replace established treatment.

Patient-first principle: The most promising cancer treatment is not necessarily the newest treatment. The appropriate therapy depends on cancer type, stage, molecular profile, prior treatment, patient health, treatment goals, clinical-trial evidence and the regulatory status of the therapy.

Commercial Scale vs. Scientific Innovation

One of the most important conclusions from this review is that commercial leadership and scientific leadership are not the same thing.

Merck can dominate oncology revenue because of Keytruda, while a much smaller biotechnology company can introduce a technology that eventually changes the entire treatment paradigm.

Gendicine is an excellent historical example. It is not comparable with Merck in revenue, global market penetration or number of approved indications. Nevertheless, its approval represented a major conceptual milestone: therapeutic genetic material could become an approved cancer medicine.

The same principle applies today to CAR-T, radioligand therapy, ADCs, bispecific antibodies and personalized cancer vaccines.

Limitations of This Ranking

• There is no universally accepted methodology for ranking oncology companies.
• Companies report oncology revenue differently.
• Some cancer products are marketed through partnerships or co-development arrangements.
• Pipeline value is inherently uncertain.
• A high oncology revenue figure does not necessarily indicate superior clinical efficacy.
• Regulatory approvals differ by country.
• Gendicine is included as a technology and historical milestone rather than as a revenue-ranked multinational pharmaceutical company.
• Clinical evidence for emerging platforms can change rapidly as randomized trials mature.

Frequently Asked Questions

What is the largest cancer drug company in 2026?

Merck remains one of the world's most commercially important oncology companies, driven particularly by Keytruda. However, the answer depends on whether "largest" means oncology revenue, total company revenue, market capitalization, pipeline value or number of marketed cancer products.

What is Gendicine?

Gendicine is a recombinant human p53 adenoviral gene therapy developed by Shenzhen SiBiono GeneTech. China approved it in 2003 for head and neck squamous cell carcinoma.

Was Gendicine the first cancer gene therapy?

Gendicine is widely described in the peer-reviewed literature as the first commercially approved human cancer gene therapy. It was approved in China in 2003.

How does Gendicine work?

Gendicine uses a replication-defective adenoviral vector to deliver a functional wild-type TP53 gene to target cells. The objective is to restore p53 tumor-suppressor activity and promote anti-tumor effects.

Is Gendicine approved worldwide?

No. Gendicine's landmark approval occurred in China. Regulatory approval in one country does not automatically establish approval or availability in another jurisdiction.

Is Gendicine an oncolytic virus?

Not in the strict mechanistic sense. Gendicine is primarily a replication-defective viral gene-delivery therapy. Oncolytic viruses are generally designed to replicate preferentially in cancer cells and destroy them through viral replication and associated immune mechanisms.

What are the most important cancer-treatment technologies in 2026?

Major areas include immune checkpoint inhibitors, targeted therapies, antibody-drug conjugates, bispecific antibodies, CAR-T and other cellular therapies, radioligand therapy, gene therapy, oncolytic viruses, protein degraders and personalized cancer vaccines.

Does a promising cancer technology mean it is proven?

No. Preclinical findings and early clinical studies can be encouraging without establishing improved survival or a favorable benefit-risk profile. Randomized clinical trials and regulatory assessment remain important for determining clinical value.

Bottom Line

The global oncology industry in 2026 is much more than a competition between traditional pharmaceutical companies.

Merck, Roche, Bristol Myers Squibb, Johnson & Johnson and AstraZeneca remain major forces because of their enormous oncology franchises. Novartis is helping define radioligand therapy, while other companies are expanding rapidly in targeted therapy, ADCs, bispecific antibodies and cellular therapy.

But the deeper story is technological.

The history of oncology is moving from cytotoxic chemotherapy → targeted therapy → immunotherapy → engineered biological therapies → increasingly personalized combinations.

Gendicine belongs in that history. Its 2003 approval demonstrated that a cancer medicine could be designed to deliver therapeutic genetic information directly into tumor tissue. More than two decades later, the same broad concept has evolved into a much larger ecosystem involving CAR-T cells, gene editing, viral vectors, RNA technologies and other forms of biological engineering.

The future of oncology is unlikely to be one "magic bullet." It is more likely to be an increasingly personalized combination of molecular targeting, immune activation, engineered biology and precise drug delivery.

For patients, clinicians and investors, the most useful question is therefore no longer simply "Which company makes the best cancer drug?" It is:

"Which therapeutic platform can most effectively match the biology of a particular cancer?"

Selected Scientific & Regulatory References

1. U.S. Food and Drug Administration. Oncology (Cancer)/Hematologic Malignancies Approval Notifications. 2026.
2. U.S. Food and Drug Administration. Verified Clinical Benefit — Cancer Accelerated Approvals.
3. Merck & Co. Full-Year 2025 Financial Results. 2026.
4. Bristol Myers Squibb. Key Facts and 2025 Product Revenue Data. 2026.
5. Johnson & Johnson. Full-Year 2025 Results and Oncology Sales. 2026.
6. Qi L, Li G, Li P, et al. Twenty years of Gendicine rAd-p53 cancer gene therapy: The first-in-class human cancer gene therapy in the era of personalized oncology. Genes & Diseases. 2024.
7. Hietanen S, et al. The First Approved Gene Therapy Product for Cancer Ad-p53 (Gendicine): 12 Years in the Clinic. Human Gene Therapy. 2018.
8. Pearson S, Jia H, Kandachi K. China approves first gene therapy. Nature Biotechnology. 2004;22:3–4.
9. Recent peer-reviewed reviews of p53-directed gene therapy and viral oncology platforms, including Gendicine, CAR-T, oncolytic viruses and next-generation targeted approaches.

Medical disclaimer: This article is for educational and informational purposes only. It is not medical advice, does not establish a treatment recommendation and should not be used to replace consultation with a qualified oncologist. Cancer treatment decisions should be based on the individual's diagnosis, stage, biomarkers, clinical condition, treatment history, applicable clinical guidelines and the best available evidence.

Editorial methodology: OneDayMD periodically updates this article as oncology approvals, clinical evidence, company portfolios and financial results change. Historical sales figures should not be interpreted as current prices, investment recommendations or measures of clinical superiority.